🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

We are excited to attend #FOCIS2025 and share how our scientists are developing effective treatments for people living with immune-mediated conditions. Learn more about being part of the next generation of immunology advancements.careers.jnj.com/en/jobs/?searc… #JNJImmunology #dedicated

The pace of innovation is on display at ASCO ! So is the promise of collaboration. Our new survey shows ~50% of HCPs want to increase collaboration across care settings. We’re working to help turn that promise into practice. jnj.com/oncology/oncol… #ASCO25 #JNJOncology

This week at Psych Congress Network, we look forward to sharing data from across our neuroscience portfolio. As we further our mission of addressing unmet needs in mental health care, these events are key moments to listen, learn, and connect with purpose. #psychcongresselevate2025

Our latest data at #ASCO25 show a clear focus: leading with precision to bring new treatment options to patients with advanced #ProstateCancer: bit.ly/3Z9YYG6 #JNJOncology

Help us find the next innovation aimed at improving non-T2 Asthma and COPD care. Submit your best ideas for an opportunity to pitch J&J leaders! jji.jnj/PRI25

We’re advancing the science of #ProstateCancer to improve outcomes for all patients with the disease. With our data at #ASCO25, we’re building upon our expertise in precision medicine: bit.ly/43tl6hn #JNJOncology

Our latest #BloodCancer research is unlocking new options for patients—driven by deep expertise of disease biology. We look forward to sharing new data on our therapy for patients with relapsed or refractory #MultipleMyeloma at #ASCO25: bit.ly/4kowp09 #JNJOncology

Help us celebrate the incredible contributions of those advancing healthcare! Nominate an outstanding scientist for the 2025 Dr. Paul Janssen Award today! #NominateNow #DrPaulJanssenAward2025 #DPJA #JanssenAward Learn more: bit.ly/3T9q5gY

2 days left! Don’t miss out. Share your novel approaches aimed to help advance precision oncology therapies for patients! Apply today bit.ly/4mLeouH #QuickFireChallenge #Gastroenterology

Don't miss your chance to nominate an outstanding scientist in the field!   Learn more: bit.ly/4kFyMfk #DrPaulJanssenAward

Ivy’s story inspires our work to help advance potential treatment options for people with warm autoimmune hemolytic anemia (wAIHA). At European Hematology Association, we’re sharing data that brings us closer to this goal. Learn more about our latest research: jnj.com/health-and-wel… #EHA2025

At #EULAR2025, we're proud to unveil new data in psoriatic arthritis (PsA), reinforcing the role of IL-23 inhibition in PsA treatment and joint improvement. Discover our latest data at EULAR: bit.ly/3Zvd2KB #JNJImmunology

#PHridayPHacts: #PulmonaryArterialHypertension is categorized into four functional classes, a commonly used term to assess the severity of the condition, evaluate the progression and determine treatments. Visit our site to learn more: emea.jnjwithme.com/en/pulmonary-a…

Our latest #BloodCancer data highlights how we’re advancing innovative therapies to transform options for patients. See how we’re showing up at #EHA25: innovativemedicine.jnj.com/newsroom?sf226… #JNJOncology

We’re proud to contribute 11 abstracts to #EAN2025 on neurological autoantibody-driven diseases, with new data exploring the importance of sustained disease control in generalized myasthenia gravis (gMG). Explore the data: jnj.com/media-center/p… #JNJNeuroscience

From AI diagnostics to patient-facing apps — these awardees’ innovations have the potential to shape the future for Japan’s aging population. Join us in congratulating the Japan Smart Healthy Aging QuickFire Challenge awardees! Learn more: jnjinnovation.com/innovation-cha…

This #WorldSclerodermaDay, we are raising awareness of this rare autoimmune disease that can lead to complications like #PulmonaryArterialHypertension (PAH). Let’s stand together to amplify the voices of those impacted and advocate for research that can lead to better treatments.

Only 2 days left to apply to the Pitching Respiratory Innovation QuickFire Challenge! Submit your best ideas for an opportunity to pitch J&J leaders! bit.ly/4lE8LNp

Today, we’re proud to share we’ve submitted a supplemental New Drug Application to the U.S. FDA for one of our schizophrenia treatments. This reflects our longstanding commitment to improving care for people living with schizophrenia. Read more: bit.ly/4lGqXpA

Share your innovations aimed at addressing hard-to-drug targets relevant to neurodegeneration of the brain and eye and/or neuropsychiatry. Eligible innovators have the opportunity for grant funding, a year-long membership to JLABS Korea and mentorship. bit.ly/4lIqiE9